(Q46951299)

26 December 2017

title

The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males (English)

1 reference

26 December 2017

8

Annamaria Colao

1 reference

26 December 2017

7

Gaetano Lombardi

1 reference

26 December 2017

Michele De Rosa

1

1 reference

26 December 2017

Antonio Ciccarelli

2

1 reference

26 December 2017

Stefano Zarrilli

3

1 reference

26 December 2017

Ermelinda Guerra

4

1 reference

26 December 2017

Maria Gaccione

5

1 reference

26 December 2017

Antonella Di Sarno

6

1 reference

26 December 2017

publication date

1 March 2006

1 reference

26 December 2017

published in

Clinical Endocrinology

1 reference

26 December 2017

volume

64

1 reference

26 December 2017

issue

3

1 reference

26 December 2017

page(s)

307-313

1 reference

26 December 2017

Ultrastructural lesions in testes from hyperprolactinemic men.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02461.X

Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02461.X

A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02461.X

Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02461.X

Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02461.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02461.X

Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02461.X

Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02461.X

Clinical significance of the Acridine Orange test performed as a routine examination: comparison with the CASA estimates and strict criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02461.X

Dopamine as a Prolactin (PRL) Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02461.X

10.1111/J.1365-2265.2006.02461.X

21 January 2018

Identifiers

DOI

1 reference

26 December 2017

PubMed ID

16487441

1 reference

26 December 2017